The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | The impact of smoking on clinical outcomes for lung cancer treatments
Jacek Jassem, MD, PhD, Medical University of Gdansk, Gdansk, Poland, discusses the effects of smoking on the clinical outcomes of lung cancer treatments. The tolerance of surgery is especially lower in patients with lung cancer who smoke, hence patients are advised to quit before procedures due to the high complication rates. Radiotherapy is suggested to exacerbate inflammatory processes and irritation, and these effects are also worsened by smoking. Systemic therapies such as molecular targeting agents are metabolised faster in smokers with lung cancer and as a result, their tolerance is increased but the efficacy of the treatment is lower. Dr Jassem emphasises that smoking has a negative impact across all modalities of lung cancer treatment. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
